(AOF) – An error crept into the title of our dispatch this morning on OPM. The net loss figure has been corrected. Oncodesign precision medicine (OPM) announces cash flow of 10 million euros at the end of 2023, which gives it financial visibility until the beginning of 2025. This biotech specializing in precision medicine for the treatment of resistant and metastatics published a net loss of 8.1 million euros for the year 2023, for a turnover of 1.1 million compared to 8 million in 2022.
OPM shows an “increase in R&D investments of 27%” to 8.8 million, mainly linked to the clinical development of OPM-101 and the start of a preclinical program in oncology OPM-102.
“One year after its debut, numerous milestones have been achieved by OPM and its teams, not the least of which, since two molecules from OPM’s Nanocyclix technology have entered the Phase I clinical phase in healthy volunteers,” comments CEO Philippe Gene.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
